시장보고서
상품코드
1297161

세계의 생명과학 툴 시장 평가 : 유형별, 기술별, 제품별, 최종사용자별, 지역별, 기회 및 예측(2016-2030년)

Life Science Tools in Healthcare Market Assessment, By Type, By Technology, By Product, By End-user, By Region, Opportunities and Forecast, 2016-2030F

발행일: | 리서치사: Market Xcel - Markets and Data | 페이지 정보: 영문 126 Pages | 배송안내 : 3-5일 (영업일 기준)


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 생명과학 툴 시장 규모는 2022년 1,512억 8,000만 달러에서 2030년 3,156억 6,000만 달러에 달할 것으로 예상되며, 2023-2030년의 예측 기간 동안 CAGR 9.63%의 CAGR을 보일 것으로 전망됩니다. 첨단 치료법 개발을 위한 바이오 제약 기업의 투자 증가, 새로운 의약품 및 치료법에 대한 수요 증가, 유세포 분석기, 분광계, 현미경, 크로마토그래피 컬럼, 핵산 처리 장비 등 기기의 급속한 채택, 암, 당뇨병, 갑상선 질환과 같은 만성 질환의 유행 등의 요인이 시장을 주도하고 있습니다. 시장을 주도하고 있습니다.

이 보고서는 세계의 생명과학 툴(Life Science Tools) 시장에 대해 조사 분석했으며, 시장 규모와 예측, 시장 역학, 주요 기업 현황 및 전망 등의 정보를 제공합니다.

목차

제1장 조사 방법

제2장 프로젝트의 범위와 정의

제3장 세계 생명과학 툴 시장에 대한 COVID-19의 영향

제4장 주요 요약

제5장 세계의 생명과학 툴 시장 전망(2016년-2030년)

  • 시장 규모와 예측
    • 매출
    • 판매 수량
  • 유형별
    • 기구
    • 소모품
    • 서비스
  • 기술별
    • 게노믹스
    • 프로테오믹스
    • 세포생물학 기술
    • 실험용품
    • 기타
  • 제품별
    • 세포배양 시스템 및 3D 세포배양
    • 액체 크로마토그래피
    • 질량분석
    • 유세포분석기
    • 클로닝 및 게놈 엔지니어링
    • 현미경 검사
    • 차세대 시퀀싱
    • PCR 및 qPCR
    • 핵산 조제
    • 핵산 마이크로어레이
    • 생어 시퀀싱
    • 트랜스펙션 기기 및 유전자 딜리버리 기술
    • 핵자기공명(NMR)
    • 기타
  • 최종사용자별
    • 의료
    • 정부 및 학술기관
    • 바이오의약품 기업
    • 산업
    • 기타
  • 지역별
    • 북미
    • 유럽
    • 남미
    • 아시아태평양
    • 중동 및 아프리카
  • 시장 점유율 : 기업별(2022년)

제6장 세계의 생명과학 툴 시장 전망 : 지역별(2016년-2030년)

  • 북미
    • 유형별
    • 기술별
    • 제품별
    • 최종사용자별
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 독일
    • 프랑스
    • 이탈리아
    • 영국
    • 러시아
    • 네덜란드
    • 스페인
    • 터키
    • 폴란드
  • 남미
    • 브라질
    • 멕시코
    • 아르헨티나
  • 아시아태평양
    • 인도
    • 중국
    • 일본
    • 호주
    • 베트남
    • 한국
    • 인도네시아
    • 필리핀
  • 중동 및 아프리카
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 남아프리카공화국

제7장 시장 매핑(2022년)

  • 유형별
  • 기술별
  • 최종사용자별
  • 제품별
  • 지역별

제8장 거시환경과 업계 구조

  • 수급 분석
  • 수출입 분석 - 수량과 금액
  • 공급/밸류체인 분석
  • PESTEL 분석
  • Porter의 Five Forces 분석

제9장 시장 역학

  • 성장 촉진요인
  • 성장 억제요인(과제, 성장 억제요인)

제10장 규제 프레임워크와 혁신

  • 임상시험
  • 특허 현황
  • 규제기관 승인
  • 혁신/최신 기술

제11장 주요 기업 상황

  • 시장 리더 주요 5개사의 경쟁 매트릭스
  • 시장 리더 주요 5개사의 시장 매출 분석(2022년)
  • 인수합병(M&A)/합작투자(해당하는 경우)
  • SWOT 분석(시장 진출기업 5개사)
  • 특허 분석(해당하는 경우)

제12장 가격 분석

제13장 사례 연구

제14장 주요 기업 전망

  • Becton, Dickinson, and Company
  • Agilent Technologies Inc.
  • Illumina Inc.
  • Thermo Fisher Scientific Inc.
  • F. Hoffmann-La Roche Ltd
  • Bio-Rad Laboratories Inc.
  • Merck KGaA
  • GE Healthcare
  • Bruker Corporation
  • Qiagen NV
  • Danaher Corporation
  • Abbott Laboratories Inc.
  • Shimadzu Corporation
  • Hitachi, Ltd.
  • Oxford Instruments plc
  • Zeiss International

제15장 전략적 추천 사항

제16장 당사에 대해/면책사항

LSH 23.07.04

Global Life Science Tools market size was valued at USD 151.28 billion in 2022 which is expected to reach USD 315.66 billion in 2030 with a CAGR of 9.63% for the forecast period between 2023 and 2030. The rapid development of life sciences tools and technologies such as gene sequencing, mass spectroscopy, chromatography, nuclear magnetic resonance (NMR), and other varied goods is contributing to innovation.

Additionally, the market is being driven by factors such as increasing investments by biopharmaceutical companies for the creation of advanced therapies, increasing need for novel medicines and treatments, rapid adoption of instruments such as flow cytometers, spectrometers, microscopes, chromatography columns, nucleic acid processing equipment and increasing prevalence of chronic diseases such as cancer, diabetes, thyroid disorders and many others.

The development of molecular diagnostic techniques such as digital droplet PCR, next-generation sequencing (NGS), and genome-wide sequencing has led to the introduction of DNA testing in clinical settings. For instance, Illumina, a global leader in DNA sequencing, and Genoscreen, a genomics company announced their partnership in October 2022 to speed up ending tuberculosis globally. This collaboration aims to enhance resources and skills in nations greatly affected by tuberculosis, such as India, to improve the efficiency of identifying and fighting against multidrug-resistant TB.

Increasing Demand for Biopharmaceuticals

The growing need for biologics, which often utilize recombinant DNA technology, is expected to fuel the expansion of the life science tools market. Biopharmaceuticals offer advantages such as increased efficacy, reduced adverse effects, minimized risk of drug interactions and improved patient outcomes. To meet the increasing demand and enhance the production of biological treatments, the life science industry is currently focusing on advanced analytical models such as predictive analytics. These cutting-edge innovations are being facilitated by significant technological improvements such as laboratory upgrades, strategic advancements, and operational optimizations. The demand for biopharmaceutical products has increased due to their enhanced safety, effectiveness, and ability to cure previously untreatable medical conditions.

Rapid Technological Advancements

Technological advancements have led to the growing utilization of various tools in the field, such as next sequencers, PCR (Polymerase Chain Reaction) and qPCR (quantitative polymerase chain reaction) machines, flow cytometers, spectrometers, microscopes, chromatography columns, nucleic acid processing equipment, and cell biology instruments. These advancements have had a significant impact on the integration of DNA assays in clinical settings, specifically in molecular diagnostic techniques like digital droplet PCR, NGS, and genome-wide sequencing. These methods have improved accuracy, timeframe, and reproducibility. To effectively harness the therapeutic potential of circulating nucleic acids, it is crucial to have an efficient extraction process.

Becton , Dickinson and Company (BD), a prominent global medical technology company, and Labcorp, a premier life sciences company, announced a strategic collaboration in August 2022. The collaboration aims to establish a framework for the development, production, marketing, and commercialization of companion diagnostics (CDx) based on flow cytometry. These CDx solutions are designed to complement the administration of potentially life-altering therapies for cancer and similar diseases.

Healthcare Sector is Experiencing Rapid Growth

The healthcare sector emerged as the leading contributor to the market value in 2022 and is expected to exhibit significant growth throughout the forecast period. This segment encompasses clinics, hospitals, community centers, diagnostic laboratories, and physician offices. The increasing adoption of proteomic and genomic workflows in hospitals for the diagnosis and treatment of various clinical abnormalities is predicted to drive market growth. The healthcare sector's expansion is primarily attributed to the extensive utilization and demand for tissue diagnostic solutions in hospitals. Clinicians are increasingly opting for tissue-based diagnostic tests over conventional methods due to their quick turnaround time. The integration of genomic sequencing in hospitals and clinical settings is predicted to improve patient care and reduce healthcare costs. This development is expected to drive the rapid growth of the healthcare sector. Furthermore, advancements in tools and equipment have significantly enhanced the accuracy of complex medical procedures in hospitals. The precision and reliability of medical diagnostic outcomes largely rely on the laboratory tools utilized for analysis, which positively impacts the expansion of the market.

For Instance, in January 2023, QIAGEN entered into an exclusive strategic agreement with Helix, a population genomics company based in California. According to the recently disclosed agreement, QIAGEN will have exclusive rights to market and handle contracts for Helix's companion diagnostic services within the United States. This collaboration will utilize the Helix Laboratory Platform, which has received the pioneering de novo class II authorization from the U.S. Food & Drug Administration for a comprehensive exome sequencing platform.

Growth of Cell and Gene Therapies is Propelling Market Growth

The utilization of genomic technologies on a global scale is on the rise, leading to advancements in diagnostic tests and procedures for various diseases and driving the growth of the market. A recent example is the commercial launch of a new molecular polymerase chain reaction (PCR) assay for the monkeypox virus by Becton, Dickinson, and Company (BD) and CerTest Biotec in September 2022, targeting both the United States and global markets. It is important to note that this PCR assay is currently intended for research purposes only. With the introduction of such innovative products, the market is expected to experience robust growth throughout the projected period. A comprehensive understanding of cell biology has emerged as an asset in laboratory workflows, creating new opportunities for market expansion. Furthermore, scientists in the life science field are keen to adopt cutting-edge instruments, which is anticipated to further strengthen this segment. Companies such as Cytiva, BioTek Instruments, Horizon Discovery, and Seahorse Bioscience are introducing instruments related to cell analysis, cell biology and imaging. The demand for tools and equipment is being propelled by the rising research and development activities conducted by prominent industrial companies.

A notable example is the strategic partnership between Haihe and EdiGene Laboratory, announced in January 2022, aimed at developing platform technologies and stem regenerative cell treatments. This collaboration focuses on exploring advanced biomarkers to enhance quality control in stem cell production.

Impact of COVID-19

The COVID-19 pandemic has had a significant impact on the life science tools industry and their respective supply chains worldwide. This disruption can be attributed to several factors, including the scarcity of raw materials and labor, as well as interruptions in the transportation of these materials across regions. As a result, there has been a shortage of critical medical supplies in different parts of the world, including molecular and immunoassay kits, digital solutions, life-support machines, and drugs. The COVID-19 pandemic had spurred a competitive race among manufacturers to create rapid diagnostics for the detection of SARS-CoV-2 virus, resulting in remarkable advancements and breakthroughs in terms of innovative solutions. These tests utilize various methods such as PCR for detecting the SARS-CoV-2 nucleic material, nucleic acid hybridization-related techniques, or serological and immunological assays for detecting antibodies produced in response to the virus.

For instance, in December 2021, Siemens Healthineers obtained emergency use authorization from the FDA for its 'Clinitest', a rapid COVID -19 antigen self-test, that can be self-administered by individuals aged 14 and above.

Key Players Landscape and Outlook

The market is characterized by strong competition as numerous players offer similar products. These players are consistently expanding their product portfolios and introducing new platforms through extensive research and development efforts to maintain their market position. Moreover, major companies are undertaking strategic initiatives such as collaborations, mergers and acquisitions, and new product launches to drive market growth and intensify competition. For example, in February 2022, Agilent Technologies, Inc. formed a partnership with Biosciences, Inc. to integrate the AVITI System with SureSelect target enrichment panels, aiming to provide customers with improved access to genomic tools. This initiative was anticipated to create fresh growth opportunities for the company.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Impact of COVID-19 on the Global Life Science Tools Market

4. Executive Summary

5. Global Life Science Tools Market Outlook, 2016-2030F

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
    • 5.1.2. By Volume
  • 5.2. By Type
    • 5.2.1. Instruments
    • 5.2.2. Consumables
    • 5.2.3. Services
  • 5.3. By Technology
    • 5.3.1. Genomics
    • 5.3.2. Proteomics
    • 5.3.3. Cell Biology Technology
    • 5.3.4. Lab Supplies
    • 5.3.5. Others
  • 5.4. By Product
    • 5.4.1. Cell Culture Systems & 3D Cell Culture
    • 5.4.2. Liquid Chromatography
    • 5.4.3. Mass Spectrometry
    • 5.4.4. Flow Cytometry
    • 5.4.5. Cloning & Genome Engineering
    • 5.4.6. Microscopy
    • 5.4.7. Next Generation Sequencing
    • 5.4.8. PCR & qPCR
    • 5.4.9. Nucleic Acid Preparation
    • 5.4.10. Nucleic Acid Microarray
    • 5.4.11. Sanger Sequencing
    • 5.4.12. Transfection Devices & Gene Delivery Technologies
    • 5.4.13. Nuclear Magnetic Resonance (NMR)
    • 5.4.14. Others
  • 5.5. By End-user
    • 5.5.1. Healthcare
      • 5.5.1.1. Hospitals
      • 5.5.1.2. Clinics
      • 5.5.1.3. Research Laboratories
      • 5.5.1.4. Diagnostic Laboratories
      • 5.5.1.5. Physician Office
      • 5.5.1.6. Community Centres
    • 5.5.2. Government & Academic Institutions
    • 5.5.3. Biopharmaceutical Company
    • 5.5.4. Industrial Applications
    • 5.5.5. Others
  • 5.6. By Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. South America
    • 5.6.4. Asia-Pacific
    • 5.6.5. Middle East and Africa
  • 5.7. By Company Market Share (%), 2022

6. Global Life Science Tools Market Outlook, By Region, 2016-2030F

  • 6.1. North America*
    • 6.1.1. By Type
      • 6.1.1.1. Instruments
      • 6.1.1.2. Consumables
      • 6.1.1.3. Services
    • 6.1.2. By Technology
      • 6.1.2.1. Genomics
      • 6.1.2.2. Proteomics
      • 6.1.2.3. Cell Biology Technology
      • 6.1.2.4. Lab Supplies
      • 6.1.2.5. Others
    • 6.1.3. By Product
      • 6.1.3.1. Cell Culture Systems & 3D Cell Culture
      • 6.1.3.2. Liquid Chromatography
      • 6.1.3.3. Mass Spectrometry
      • 6.1.3.4. Flow Cytometry
      • 6.1.3.5. Cloning & Genome Engineering
      • 6.1.3.6. Microscopy
      • 6.1.3.7. Next Generation Sequencing
      • 6.1.3.8. PCR & qPCR
      • 6.1.3.9. Nucleic Acid Preparation
      • 6.1.3.10. Nucleic Acid Microarray
      • 6.1.3.11. Sanger Sequencing
      • 6.1.3.12. Transfection Devices & Gene Delivery Technologies
      • 6.1.3.13. Nuclear Magnetic Resonance (NMR)
      • 6.1.3.14. Others
    • 6.1.4. By End-user
      • 6.1.4.1. Healthcare
      • 6.1.4.1.1. Hospitals
      • 6.1.4.1.2. Clinics
      • 6.1.4.1.3. Research Laboratories
      • 6.1.4.1.4. Diagnostic Laboratories
      • 6.1.4.1.5. Physician Office
      • 6.1.4.1.6. Community Centres
      • 6.1.4.2. Government & Academic Institutions
      • 6.1.4.3. Biopharmaceutical Company
      • 6.1.4.4. Industrial Applications
      • 6.1.4.5. Others
    • 6.1.5. United States*
      • 6.1.5.1. By Type
      • 6.1.5.1.1. Instruments
      • 6.1.5.1.2. Consumables
      • 6.1.5.1.3. Services
      • 6.1.5.2. By Technology
      • 6.1.5.2.1. Genomics
      • 6.1.5.2.2. Proteomics
      • 6.1.5.2.3. Cell Biology Technology
      • 6.1.5.2.4. Lab Supplies
      • 6.1.5.2.5. Others
      • 6.1.5.3. By Product
      • 6.1.5.3.1. Cell Culture Systems & 3D Cell Culture
      • 6.1.5.3.2. Liquid Chromatography
      • 6.1.5.3.3. Mass Spectrometry
      • 6.1.5.3.4. Flow Cytometry
      • 6.1.5.3.5. Cloning & Genome Engineering
      • 6.1.5.3.6. Microscopy
      • 6.1.5.3.7. Next Generation Sequencing
      • 6.1.5.3.8. PCR & qPCR
      • 6.1.5.3.9. Nucleic Acid Preparation
      • 6.1.5.3.10. Nucleic Acid Microarray
      • 6.1.5.3.11. Sanger Sequencing
      • 6.1.5.3.12. Transfection Devices & Gene Delivery Technologies
      • 6.1.5.3.13. Nuclear Magnetic Resonance (NMR)
      • 6.1.5.3.14. Others
      • 6.1.5.4. By End-user
      • 6.1.5.4.1. Healthcare
      • 6.1.5.4.1.1. Hospitals
      • 6.1.5.4.1.2. Clinics
      • 6.1.5.4.1.3. Research Laboratories
      • 6.1.5.4.1.4. Diagnostic Laboratories
      • 6.1.5.4.1.5. Physician Office
      • 6.1.5.4.1.6. Community Centres
      • 6.1.5.4.2. Government & Academic Institutions
      • 6.1.5.4.3. Biopharmaceutical Company
      • 6.1.5.4.4. Industrial Applications
      • 6.1.5.4.5. Others
    • 6.1.6. Canada
    • 6.1.7. Mexico

All segments will be provided for all regions and countries covered

  • 6.2. Europe
    • 6.2.1. Germany
    • 6.2.2. France
    • 6.2.3. Italy
    • 6.2.4. United Kingdom
    • 6.2.5. Russia
    • 6.2.6. Netherlands
    • 6.2.7. Spain
    • 6.2.8. Turkey
    • 6.2.9. Poland
  • 6.3. South America
    • 6.3.1. Brazil
    • 6.3.2. Mexico
    • 6.3.3. Argentina
  • 6.4. Asia-Pacific
    • 6.4.1. India
    • 6.4.2. China
    • 6.4.3. Japan
    • 6.4.4. Australia
    • 6.4.5. Vietnam
    • 6.4.6. South Korea
    • 6.4.7. Indonesia
    • 6.4.8. Philippines
  • 6.5. Middle East & Africa
    • 6.5.1. Saudi Arabia
    • 6.5.2. UAE
    • 6.5.3. South Africa

7. Market Mapping, 2022

  • 7.1. By Type
  • 7.2. By Technology
  • 7.3. By End-user
  • 7.4. By Product
  • 7.5. By Region

8. Macro Environment and Industry Structure

  • 8.1. Supply Demand Analysis
  • 8.2. Import Export Analysis - Volume and Value
  • 8.3. Supply/Value Chain Analysis
  • 8.4. PESTEL Analysis
    • 8.4.1. Political Factors
    • 8.4.2. Economic System
    • 8.4.3. Social Implications
    • 8.4.4. Technological Advancements
    • 8.4.5. Environmental Impacts
    • 8.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 8.5. Porter's Five Forces Analysis
    • 8.5.1. Supplier Power
    • 8.5.2. Buyer Power
    • 8.5.3. Substitution Threat
    • 8.5.4. Threat from New Entrant
    • 8.5.5. Competitive Rivalry

9. Market Dynamics

  • 9.1. Growth Drivers
  • 9.2. Growth Inhibitors (Challenges, Restraints)

10. Regulatory Framework and Innovation

  • 10.1. Clinical Trials
  • 10.2. Patent Landscape
  • 10.3. Regulatory Approvals
  • 10.4. Innovations/Emerging Technologies

11. Key Players Landscape

  • 11.1. Competition Matrix of Top Five Market Leaders
  • 11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2022)
  • 11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 11.4. SWOT Analysis (For Five Market Players)
  • 11.5. Patent Analysis (If Applicable)

12. Pricing Analysis

13. Case Studies

14. Key Players Outlook

  • 14.1. Becton, Dickinson, and Company
    • 14.1.1. Company Details
    • 14.1.2. Key Management Personnel
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As reported)
    • 14.1.5. Key Market Focus & Geographical Presence
    • 14.1.6. Recent Developments
  • 14.2. Agilent Technologies Inc.
  • 14.3. Illumina Inc.
  • 14.4. Thermo Fisher Scientific Inc.
  • 14.5. F. Hoffmann-La Roche Ltd
  • 14.6. Bio-Rad Laboratories Inc.
  • 14.7. Merck KGaA
  • 14.8. GE Healthcare
  • 14.9. Bruker Corporation
  • 14.10. Qiagen NV
  • 14.11. Danaher Corporation
  • 14.12. Abbott Laboratories Inc.
  • 14.13. Shimadzu Corporation
  • 14.14. Hitachi, Ltd.
  • 14.15. Oxford Instruments plc
  • 14.16. Zeiss International

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

15. Strategic Recommendations

16. About Us & Disclaimer

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제